Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
The company plans to submit the IND application by the end of 2021
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
The company does not expect the outcome of this inspection to impact its plans
The company is the Clinical Research Organisation of Caplin Point Laboratories
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Subscribe To Our Newsletter & Stay Updated
